Company Description
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema.
It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis.
Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 6, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 403 |
| CEO | John Leonard |
Contact Details
Address: 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 United States | |
| Phone | 857 285 6200 |
| Website | intelliatx.com |
Stock Details
| Ticker Symbol | NTLA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001652130 |
| CUSIP Number | 45826J105 |
| ISIN Number | US45826J1051 |
| Employer ID | 36-4785571 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laura Sepp-Lorenzino Ph.D. | Special Advisor to the Chief Executive Officer |
| Dr. John M. Leonard M.D. | President, Chief Executive Officer and Director |
| Edward J. Dulac III | Executive Vice President, Chief Financial Officer and Treasurer |
| Michael P. Dube | Vice President, CAO and Principal Accounting Officer |
| James E. Basta Esq., J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. David Lebwohl M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder |
| Dr. Jennifer A. Doudna Ph.D. | Founder and Member of Scientific Advisor Board |
| Dr. Derrick J. Rossi Ph.D. | Founder and Member of Scientific Advisor Board |
| Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder and Member of Scientific Advisor Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 28, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 13, 2025 | SCHEDULE 13G | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |